Aldeyra Therapeutics, Inc.
ALDX Real Time Price USDRecent trades of ALDX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ALDX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
ALDX Revenue by Segment or Geography
New patents grants
-
Patent Title: Deuterated compounds and uses thereof Mar. 04, 2025
-
Patent Title: Toxic aldehyde related diseases and treatment Oct. 29, 2024
-
Patent Title: Process for preparation of aldehyde scavenger and intermediates Sep. 24, 2024
-
Patent Title: Compositions and methods for the treatment of macular degeneration Sep. 24, 2024
-
Patent Title: Pharmaceutical formulations and uses thereof Aug. 20, 2024
-
Patent Title: Polymorphic compounds and uses thereof Jul. 09, 2024
-
Patent Title: Polymorphic compounds and uses thereof Jun. 11, 2024
-
Patent Title: Ophthalmic formulations of methotrexate Jun. 11, 2024
-
Patent Title: Ophthalmic formulations of methotrexate Jun. 11, 2024
-
Patent Title: Methotrexate treatment methods Feb. 27, 2024
-
Patent Title: Deuterated compounds and uses thereof Dec. 19, 2023
-
Patent Title: Ophthalmic formulations and uses thereof Oct. 17, 2023
-
Patent Title: Toxic aldehyde related diseases and treatment Oct. 03, 2023
-
Patent Title: Compositions and methods of treating retinal disease Aug. 15, 2023
-
Patent Title: Toxic aldehyde related diseases and treatment Jul. 18, 2023
-
Patent Title: Treatment of inflammatory disorders Feb. 21, 2023
-
Patent Title: Deuterated compounds and uses thereof Oct. 04, 2022
-
Patent Title: Polymorphic compounds and uses thereof Apr. 26, 2022
-
Patent Title: Formulations for treatment of dry eye disease Dec. 14, 2021
-
Patent Title: Combination treatment of ocular inflammatory disorders and diseases Sep. 28, 2021
-
Patent Title: Deuterated compounds and uses thereof Jun. 29, 2021
-
Patent Title: Treatment of inflammatory disorders Jun. 22, 2021
-
Patent Title: Toxic aldehyde related diseases and treatment May. 18, 2021
-
Patent Title: Compositions and methods of treating retinal disease Feb. 09, 2021
-
Patent Title: Toxic aldehyde related diseases and treatment Mar. 17, 2020
-
Patent Title: Deuterated compounds and uses thereof Feb. 04, 2020
-
Patent Title: Toxic aldehyde related diseases and treatment Jan. 28, 2020
-
Patent Title: Treatment of allergic eye conditions with cyclodextrins Oct. 01, 2019
-
Patent Title: Polymorphic compounds and uses thereof Sep. 17, 2019
-
Patent Title: Toxic aldehyde related diseases and treatment Feb. 26, 2019
-
Patent Title: Compositions and methods of treating retinal disease Feb. 12, 2019
-
Patent Title: Traps in the treatment of macular degeneration Oct. 30, 2018
-
Patent Title: Compositions and methods of treating retinal disease Feb. 20, 2018
-
Patent Title: Compositions and methods for the treatment of macular degeneration Nov. 14, 2017
-
Patent Title: Toxic aldehyde related diseases and treatment Jun. 27, 2017
-
Patent Title: Compositions and methods of treating retinal disease May. 16, 2017
-
Patent Title: Peri-carbinols Mar. 28, 2017
-
Patent Title: Compositions and methods of treating retinal disease Jun. 14, 2016
-
Patent Title: Compositions and methods of treating retinal disease Feb. 23, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ALDX
Recent picks made for ALDX stock on CNBC
ETFs with the largest estimated holdings in ALDX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ALDX stock a Buy, Sell, or Hold?
- What is the price target for $ALDX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ALDX stock?
- Who owns the most shares of $ALDX stock?
- What funds own $ALDX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALDX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.